Navigation Links
Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
Date:10/27/2010

CRANFORD, N.J., Oct. 27 /PRNewswire/ -- Alan L. Rubino, former Hoffmann-La Roche senior executive and former CEO of two emerging pharmaceutical companies, and Timothy G. Rothwell, former Chairman, CEO, and President of sanofi-aventis U.S., have collaborated to form New American Therapeutics, Inc.  

Mr. Rubino will serve as CEO and President, while Mr. Rothwell will function as the company's Chairman.  The company's key emphasis will be on establishing a general specialty pharmaceutical presence built around select physician specialties and associated patient therapeutic needs.

"The decision to start New American Therapeutics was driven by changing industry trends and market forces," said Mr. Rubino. "We saw an opportunity to create a new and agile business model that is flexible and versatile enough to navigate the challenges in today's dynamic environment. The industry experience and performance track records of our leaders, board members, and management team provide us with a keen understanding of what works and what doesn't."

New American Therapeutics is being funded through a partnership with Deerfield Management Company, L.P.   Deerfield is a privately owned healthcare investment management firm that was founded in 1994 and is based in New York, N.Y.  Piper Jaffray & Co. served as exclusive financial advisor to the company on its initial financing transaction.

On October 1, 2010, New American Therapeutics announced that it acquired all U.S. rights to manufacture, market and sell the topical antiviral drug Denavir® (www.denavir.com).  A proven treatment for cold sores since 1996, Denavir is the first product the company will be marketing and distributing.

"This was an opportunistic acquisition for us that met very specific criteria," explained Mr. Rubino. "It is an excellent therapeutic agent that, despite not receiving an adequate marketing investment, was still maintaining nearly a 50% prescription share of the topical antiviral market. That speaks volumes about physician and patient satisfaction."

Because of its current level of use in the marketplace coupled with a renewed commercial effort, Denavir is expected to provide a solid financial foundation for New American Therapeutics and will serve as the company's initial anchor product.

Beyond Denavir, New American Therapeutics will be pursuing marketed and launched assets that will benefit from the company's commercialization model. "Our progressive business strategy is already in the execution phase," said Mr. Rubino. "We will be tapping into our deep relationships within many U.S. and international pharmaceutical companies to explore product acquisition opportunities and other collaborations. We intend to move quickly and bring in products at a steady rate, which will allow us to grow in a rapid, yet calculated manner."

For more information about New American Therapeutics, visit www.natxcorp.com or call 908-282-7441.

About New American Therapeutics, Inc.New American Therapeutics, Inc. is a privately held general specialty pharmaceutical company based in Cranford, N.J. that acquires, markets and distributes products that have the potential to improve outcomes for patients and provide more treatment options for physicians. CONTACT:Alan L. Rubino  908-372-8108Email: arubino@natxcorp.com
'/>"/>

SOURCE New American Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wound Management Technologies, Inc. Furthers its Government Initiatives and Business Development within the Veterans Health Administration
2. Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President
3. Medical Cannabis University™ Launches, Puts Thousands Back to Work to Help Veterans and the Chronically Ill
4. ZS Associates Appoints Pharmaceutical Industry Veteran to Serve the Firms Growing Client Base in Germany
5. Veteran Affairs Announces That Redsense Alarm Will be Mandatory on Patients by November 1, 2010
6. Veterans Administration Health Care System Purchases 15 Zargis Cardioscan Systems
7. Sperian Respiratory Protection USA Awarded a 65,000 Reusable Respirator Order by the Veterans Health Administration
8. Veteran International Health Care Executive Appointed CEO of BeneChill(R)
9. PTCB Certification Required for Pharmacy Technician Employment by Department of Veterans Affairs
10. Department of Veterans Affairs Requires PTCB Certification for Pharmacy Technician Employment
11. MyPunchbowl Expands Leadership Team With Veterans of Evite.com and Pizza Hut
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):